Revolutionizing mRNA for Life · Key Company Highlights CureVac Investor Handout, October 2020 | 3 Strategic partnerships for clinical development and commercialization support Pioneer

Investor Presentation, 7 October 2020

Revolutionizing mRNA for Life

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the “company”) contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Forward-Looking Statements

| 2CureVac Investor Handout, October 2020

Key Company Highlights


Strategic partnerships for clinical development and commercialization support

Pioneer in developing mRNA medicines in immune-active and immune-silent area

Unique technology platform for natural mRNA with low dose and potentially long-lasting immune responses

Deep pipeline across prophylactic vaccines, oncology and protein therapies

Accelerated timeline for COVID-19 vaccine candidate with phase 2 trial ongoing

In-house GMP manufacturing scale up to potentially supply billions of vaccine doses*

1

2

3

4

5

6

*Dose dependent – current estimate based on results seen in rabies vaccine trials

Differentiated Technology Creates A New Class of Products

Immune Active Immune Silent

CureVac‘s optimized mRNA and production

CureVac Investor Handout, October 2020 | 4

Lead

Product

Candidates

Formulation LNP based Peptide based LNP based Polymer based

Genmab collaboration

CRISPR collaboration CV8102

COVID-19 CVnCoV

Rabies CV7202

Tumor-associated antigens

Shared neo-antigens

Vaccines/Oncology

Antibody responses

T-cell responses

Breaking of tolerance

Area

Oncology

Innate and adaptive immunity

Oncology-Protein Therapy

Liver as target

Liver as bioreactor

Limited immunogenicity

Protein Therapy

Ocular administration

Mucosal delivery

Other (e.g. implants)

Ocular targets

Lung targets

PROGRAMS AND INDICATIONS COLLABORATIONS

PRE-CLINICAL

DISCOVERY

PRE-CLINICAL

DEVELOPMENT PH 1 PH 2 PH 3

CUREVAC

COMMERCIAL RIGHTS

PROPHYLACTIC VACCINES

DisruptiveLow doseSpeed

CVnCoV: COVID-19 Worldwide

CV7202: Rabies Worldwide

Lassa, Yellow Fever Worldwide

Respirational Syncytial Virus Worldwide

Other Infectious DiseasesEligible for milestones and royalties

Diverse projects (Rota, Malaria, Universal Influenza) Worldwide

ONCOLOGY

Intratumoral

CV8102: cMEL, ACC, SCC, HNSCC Worldwide

BI13618409 (CV9202): Non-Small Cell Lung CancerEligible for milestones and royalties

Tumor Associated Antigens Worldwide

Shared neo-antigen Worldwide

PROTEINTHERAPY

Rare DiseaseGene EditingAntibodies

Cas9 Gene-editing Eligible for milestones and royalties

Liver Metabolic Disorders (Rare Diseases, Fibrosis) Worldwide

Ocular Diseases Worldwide

Lung Respiratory Diseases Worldwide

Therapeutic AntibodiesEligible for milestones and royalties

CureVac Pipeline: A Diversified Portfolio


(1)

(1) CEPI committed to provide funding, which will be used for a Phase 1 clinical trialcMEL: Cutaneous melanoma; ACC: Adenoidcystic carcinoma; SCC: Squamous cell carcinoma; HNSCC: Squamous cell carcinoma of head and neck

GlaxoSmithKline & CureVac:Strategic mRNA Technology Collaboration

PARTNERSHIP SCOPE

4-year strategic technology collaboration

Up to 5 mRNA vaccines and monoclonal antibodiesin infectious diseases

FINANCIALS

€150m equity investment

€120m upfront payment

€30m one-time reservation fee for manufacturing capacity

Developmental, regulatory and commercial milestones

Tiered royalties on net sales


Preclinical- to Phase I clinical-development

GMP manufacturing of product candidates, including for commercialization

Commercialization rights for selected countries

Development beyond Phase I

Commercialization

© picture alliance/dpa

RNAoptimizer® - Platform Overview

RNAoptimizer® Creates Unique Product Candidates


Protein Therapy

RNAoptimizer®

Focus areasTarget expression profile

1.

ProteinDesign

2.

mRNA Optimization

3.

mRNA Delivery

Prophylactic Vaccines

Oncology

Optimal mRNA solutions for each target indication

New and exclusive IP protection for each product candidate

Identification for each mRNA product candidate

Core CureVac technology

1. Protein Design: Enables the Optimization of Specific Properties of the Encoded Protein


Area Prophylactic Vaccines

Oligomerization

Tumor growth inhibited in murine melanoma model

Higher induction of neutralizing antibodies demonstrated via optimized mRNA

Area Oncology

Modified immunogenicity

Area Protein Therapies

Extended half-life of secreted protein

Relevant serum titers of functional Epo and different pharmacokinetic profiles

Modification of Amino acid sequence for optimized protein properties including:oligomerization, half-life, stabilization of tertiary structure, secretion and immunogenicity

0

100

200

300

400

buffer design 1 design 2

**

PR

NT

50

tite

r

0

100

200

300

400

500

0 5 10 15 20 25

Me

dia

n tu

mo

rvo

lum

e[m

m³]

Days after tumor challenge

0

2000

4000

6000

1 4 7 10 13 16 19 22

Mm

Ep

o/

ng

/ m

L

Days

Designed mouse Erythropoetin mRNA

Mouse Erythropoetin mRNA

2.8 µg rec. Epo / mouse

2. mRNA Optimization: Enhanced Protein Expression and Stability of Unmodified mRNA


CureVac utilizes unmodified mRNA to extensively tailor mRNA UTRs

Identification of most potent, tissue specific regulatory elements

Screening of distinct mRNAs in cells

Open Reading Frame

Protein coding part5‘UTRs 3‘UTRs

Cas9 optimization for higher expression:

83 distinct UTR combinations for the same ORF

mRNA Optimization Case Study

Optimization of translation, stability and immunogenicity

mRNA elements optimization, including 5’ cap, 5’ UTR, ORF, 3’ UTR, 3’ poly-A tail, 3’ end

3‘ UTRsribosome5‘ UTRs

UTR: Untranslated region; ORF: Open reading frame

5‘UTRs 3‘UTRsORF

0

200

400

600

Cas9 e

xpre

ssio

n level in

HepG

2cells

Alreadyoptimizedconstruct

~ 5x in 2 weeks

1 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80

3. mRNA Delivery: Diverse Portfolio of Delivery Systems For Different Applications

Potency of administrated mRNA is the combination of mRNA efficacy and delivery system


Partner lipid nanoparticle technologies

State of the art LNP technologies

Access to lipid libraries

Used in current clinical programs (CV7202 and CVnCoV)

Systemic delivery to muscle (vaccines)

CureVac proprietary lipid nanoparticle technology

Focus on proprietary solutions

Expected use in future clinical programs

Competitive profile to partner LNPs

Delivery to muscle (vaccine) and liver (rare diseases and secreted targets)

CureVac proprietary CVCM Technology

Polymeric system

Low immunogenicity

Highly tolerable

Resistant to physical stress

Local application in tissues where lipids are not ideal (eye, lung, mucosal)

Enables selection of the most suited delivery system based on factors including:

Immunogenicity

Duration of treatment

Dose levels

Mode of administration

Targeted tissue type

CureVac Unique Mechanism of Action: Driver of Immunotherapy and Infectious Disease Programs


Unique Mechanism of Action

Validated in humans

Inducing type I interferons

Inducing B and T cell responses

Activating innate immune system

Inducing boostable memory responses

Prophylactic vaccines

Highly efficient at low dose in humans

Highly synergistic platform, multivalent vaccines possible

Fast GMP production, large scale market relevant

Automated portable manufacturing in development

Multiple product candidates in development

Cancer vaccines

Broad activation of innate & adaptive immune responses

Key activation of strong T cell responses

IFN type I response beneficial

Breaking of tolerance demonstrated

Multiple product candidates in development

PROPHYLACTIC VACCINESONCOLOGY

© picture alliance/dpa

Prophylactic Vaccines

CureVac Investor Handout, October 2020

WHO correlate of protection

≥0.5IU/mL

1µg CV7202, 2 doses:day 1 and day 29

n=8

2µg CV7202, 2 doses:day 1 and day 29

n=7

Rabies Vaccine CV7202 Induces Protective Antibody Titers at Investigated Dose Level of 1µg and 2µg

Human data (healthy volunteers): Rabies Vaccine CV7202 – Prime and Boost Regimen


Preliminary dataValues <LLOQ are shown as half LLOQ

All volunteers protected after the 2nd shot of 1µg or 2µg rabies vaccine

Detectable VNTs 8 days after 1st shot of rabies vaccine in some subjects

After two doses of 1µg or 2µg, all subjects with available data had VNTs above WHO recommended antibody level, 14 days after dose 2 (Day 43)

Vaccinations well tolerated, no SAEs reported

Current follow-up at 6 month: stable antibody titers

VNT: Virus neutralizing titer; IU: International units; LLOQ: Lower limit of quantification; WHO: World Health Organization; SAE: Serious adverse effects

0,01

0,1

1

10

100

1 8 15 22 29 36 43

VN

T (

IU/m

l)

Trial Day

1µg CV7202

0,01

0,1

1

10

100

1 8 15 22 29 36 43V

NT

(IU

/ml)

Trial Day

LLOQ

2µg CV7202


Rabies Vaccine CV7202 Demonstrates Long Durability Across All Doses

mRNA rabies vaccine induces high titers on virus-neutralizing antibodies after a single shot vaccination

Multivalent mRNA flu vaccine demonstrated strong and durable immunogenicity in non-human primates (NHP)


50 100

150

200

250

300

350

400

450

500

550

600

days post vaccination

HI t

iter

1 µg LNP injections

10 µg LNP injections

5

20

40

80

160

320

640

1280

2650

280

10

0.1

1

10

100

Days post vaccination

VN

T (

IU

/m

l)

037142128 64 92 120

148

176

204

232

288

344

100µg LNP injection

Data for H1N1 strain

VNT: Virus neutralizing titer; IU: International units; HI: hemagglutination inhibition; LNP: Lipid nanoparticles


100µg LNP injection 10µg LNP injection

1µg LNP injection

COVID-19 Vaccine Candidate CVnCoV Induces Strong and Balanced Immune Response

SARS-CoV-2 mRNA vaccine, CVnCoV, is immunogenic in mice and induces IFN type 1 mediated immune responses


d28d0 d49

VNT: Virus neutralizing titer


Virus neutralizing antibodyagainst SARS-CoV-2

Convalescent patients

*Highest tested dilution

• mRNA vaccine candidate (2µg)

• Recombinant protein/Alum (1.5µg)

• Buffer

IgG1 IgG2a

COVID-19 Vaccine Candidate CVnCoV Induces Strong T Cell Response

CVnCoV induces multifunctional (IFN+ and TNF+) CD4 and CD8 T cell responses


d28d0 d49


•mRNA vaccine candidate (2µg)

• Recombinant protein/Alum (1.5µg)

• Buffer

Accelerated Timeline to Develop COVID-19 Vaccine

Current Stage of CVnCoV:SARS-CoV-2 Efforts*


*Timeline shown is estimated and subject to various risks and uncertainties

2020 Q4

Phase 1 trials and readout

Dose escalation stage Data read-out in Q4 2020:

Safety data Antibody titers T-cell analyses

Ongoing

Complete pre-clinical evaluation of 2 candidates

Produce material for human trial (Phase I)

Design and produce 2 vaccine candidates

Q3Q2Q1


Phase 2a trials and readout

Testing in older adults Testing in high-incidence

COVID regions (Peru/Panama) Data read-out in Q4 2020

Ongoing

Clinical Development of COVID-19 Vaccine

Phase 1 Clinical Trial: Ongoing since June 2020

Partially blinded, placebo-controlled dose escalation study

Positive recommendation from DSMB for full recruitment in the currently tested dose levels: 2, 4, 6, 8, 12µg

Study population: adults 18-60 years of age

Primary endpoint: safety

Secondary endpoint: number of subjects seroconverting for SARS-CoV-2 neutralizing antibodies

Trial includes three active clinical sites in Germany and one active clinical site in Belgium

The trial has currently recruited >250 subjects across the five tested dose levels

Four dose levels are fully recruited and one dose level is currently completing recruitment



Phase 2a Clinical Trial: Ongoing since September 2020

Partially observer-blind, multicenter, controlled, dose-confirmation trial

Evaluation of safety, reactogenicity and immuno-genicity at 6 and 8µg dose levels

Study population: adults >60 and 18-60 years of age

Primary endpoint: safety

Secondary endpoint: number of subjects seroconverting for SARS-CoV-2 neutralizing antibodies

Trial is being conducted in Peru and Panama, both countries with high-incidence COVID-19 infections

A total of 690 participants will be enrolled

First comprehensive data of Phase 2a in older adults are expected later in the fourth quarter 2020

Clinical Development of COVID-19 Vaccine



Pivotal phase 2b/3 Clinical Trial: Expected to Start Q4 2020

Expected number of participants:

~30,000

Global trial to be conducted in

Europe, Latin America, Africa and Asia

First data read-out

Potentially in H1 2021

Phase 2b part of the trial

Randomized 1:1 to receive 2 doses of CVnCoV or control

Subjects stratified according to age: ≥18 and ≥ 60 years

Testing for safety, reactogenicity and immunogenicity

Phase 3 part of the trial

Randomized 1:1 to receive 2 doses of CVnCoV or control

Subjects stratified according to age: ≥18 years

Testing for efficacy and safety

Oncology

TREATED TUMOR LESION

Induction of cytokines, chemokines

Cell damage, antigen release, and antigen presentation

Recruitment and activation of innate immune cells

NK and T cell recruitment and activation

Tumor growth inhibition

CV8102: From Local Immune Activation to Systemic Immune Responses


DRAINING LYMPH NODE

Recruitment and activation of immune cells

Antigen presentation and T cell priming

NK, T- and B-cell activation and expansion

CV8102 targets immune receptors TLR 7, TLR8 and RIG-I

ONCOLOGY

DISTAL TUMORS

Tumor growth inhibition mediated by systemic T-cell responses

Amplification of immune response

NK cells: Natural killer cells

CV8102: Preliminary Efficacy Data

Preliminary data on overall tumor response and duration according to RECIST 1.1 as of April 2020


Observed 1 CR and 1 PR

2 SD and shrinkage of non-injected lesions

Overall 8 of 24 patients progression free for at least 6 months

Preliminary efficacy data:

single agent

Preliminary efficacy data:combination with PD-1 antibodies

No OR observed to date

Out of 16 patients, 1 PD-1 refractory patient with HNSCC and 1 PD-1 refractory melanoma patient with SD after 8 CV8102 injections

Patients more heavily pre-treated than patients in single agent cohort

54% pts anti-PD-1 pre-treated8% pts Ipilimumab pre-treated

ONCOLOGY

88% pts anti-PD-1 pre-treated 50% pts

Ipilimumab pre-treated

13 injectionsCV8102

CV8102: Monotherapy Case Studies


Lesionpre-treatment

5 injections CV8102

74-year-old female patient, stage IIIc melanoma with multifocal in-transit metastases

CR of injected and non-injected cutaneous lesions

CR of subcutaneous lesion (MRI)

Marked transient rise in serum IL-6 and CRP following the first intra-tumoral injection

Partial regression of injected tumor lesion after 5 injections

CR of in-transit metastases on MRI, CR of all skin metastases at week 12

Patient continued to receive injections at monthly intervals for 9 months without recurrence

Case study 1150 µg Complete Response (CR)

Case study 2100 µg CV8102

91-year-old male patient, stage IV HNSCC with large buccal and small lip lesion and a contralateral cervical metastatic LN, pretreated with cetuximab, external beam radiation and multiple surgeries

Buccal and lip lesions remained stable for 9 months (study duration)

Untreated metastatic LN showed ongoing regression

Overall stable disease according to RECIST 1.1 for 9 months

Early increase in IL-6

Metastatic LN pre-treatment

6 injectionsCV8102

8 injections CV8102

ONCOLOGY

LN: Lymph node

Pre-treatment8 injections

CV8102

Case study 3 100 µg CV8102

50-year-old female patient, patient with anti-PD-1

refractory melanoma, stage IV N3c M1b at study entry, early progression on adjuvant Nivolumab treatment

Tumor shrinkage in non-target lesions after 8 injections

Reported strong increased in quality of life

0

200

400

600

800

-20 -10 0 10 20 30 40 50 60 70 80

LD

H [

U/L

]

Trail day

CureVac TAA Vaccines Demonstrate Breaking of Tolerance in Murine Melanoma Model

Sequence optimization: increased anti-tumoral response after i.d. vaccination in B16-F10 melanoma model


0 1 0 2 0 3 0 4 0

0

1 0 0

2 0 0

3 0 0

4 0 0

T u m o r g ro w th k in e t ic s o f s .c . B 1 6 -F 1 0 tu m o rs

D a y s a fte r tu m o r c h a lle n g e

Me

dia

n tu

mo

r v

olu

me

[

mm

3]

Unst im

ula

ted

Trp

2 S

VYD

FFVW

L

Trp

2 P

ep M

ix

contr

ol pept ide

0 .0

0 .5

1 .0

1 .5

2 .0

I n d u c t io n o f m u lt ifu c t io n a l C D 8+

T c e l ls

%I

FN

+

TN

F

+ o

f C

D8

+ T

ce

lls

T rp 2 W T a n t ig e n

T r p 2 O p t im iz e d a n t ig e n d e s ig n

C t l v a c c in e

Unst im

ula

ted

Trp

2 S

VYD

FFVW

L

Trp

2 P

ep M

ix

contr

ol pept ide

0 .0

0 .5

1 .0

1 .5

2 .0


T c e l ls

%I

FN

+

TN

F

+ o

f C

D8

+ T

ce

lls



C t l v a c c in e

Unst im

ula

ted

Trp

2 S

VYD

FFVW

L

Trp

2 P

ep M

ix

contr

ol pept ide

0 .0

0 .5

1 .0

1 .5

2 .0


T c e l ls

%I

FN

+

TN

F

+ o

f C

D8

+ T

ce

lls



C t l v a c c in e

As demonstrated in rabies, LNP formulated unmodified mRNA is safe, potent, induces IFN type I response and induces B and T cells responses

ONCOLOGY

Tumor growthkinetics

Induction of multifunctional CD8+ T cells

Vitiligo effect demonstrating breaking of tolerance

Unstimulated Trp2 peptide

0.0

0.2

0.4

0.6

% I

FNγ+

TN

Fα

+of

CD

8+

T c

ells

0 10 20 30 40

Days after tumor challenge

0

100

200

300

400

Media

n t

um

or

volu

me

[mm

³]

Protein Therapy


Liver Fibrosis: An Attractive Indication for mRNA Therapy

Why liver fibrosis? Approach and key preclinical data

Common outcome of chronic liver disease leading to liver cirrhosis and hepatocellular carcinoma

Causes 2 million deaths a year

Transient treatment can be sufficient

Target: down regulated intracellular protein

Delivery to fibrotic liver possible

Repetitive administration well tolerated (8 weekly doses, 2mg/kg)

Therapeutic effect demonstrated in 3 fibrotic disease models

Significant reduction of fibrosis markers, hydroxyproline, Col2A1, a-SMA

Significant reduction of liver damage marker (ALT, AST)


Buffer control mRNA/LNP mRNA/LNP

collagen

Desm

in(a

ctivate

d

ste

llate

cells)

Lucifera

se e

xpre

ssio

n in liv

er

Healthy Fibrotic (CCL4)

PROTEIN DELIVERY

D0 D22 D27 D32 D37 D42 D4/ D52 D57 D57+6h

D61

TF mRNA / LNP treatment

CCL4-mediated induction of fibrosis

High Systemic Titers Leading to First-ever Public mRNA Antibody Deal with Genmab

Deal highlights Financials

First-ever public mRNA antibody deal

Both companies to conduct joint research on first program until IND

Option for Genmab to initiate three additional programs

CureVac retains option to participate in development and commercialization of one of the potential additional programs

CureVac to optimize and manufacture mRNA encoded antibodies for Genmab

CureVac receives $10m upfront

Genmab invests $22m(1) in CureVac equity

CureVac eligible to receive milestones between $275m and $368m for each of the potential product candidates

CureVac is eligible to receive tiered royalties in the range from mid-single digits up to low teens per product


PROTEIN DELIVERY

Manufacturing


GMP: Up-scaled Process Approved, Large Scale Financed

CureVac has 3 approved GMP suites including a newly approved up-scaled suite;

GMP IV is currently being built financed by the European Investment Bank (EIB)


GMP I and GMP II GMP III GMP IV

Location Tübingen Tübingen Tübingen

Availability Now Now Shell constructed

Supply Phase I/IIPhase I, II, III

initial market supplyPhase III,

market supply

Recently Approved

The 4th GMP facility is being designed to cover all manufacturing steps from starting material to formulation and will allow for an

annual output in the kilogram scale

Currently Financed by EIB

Revolutionizing GMP Process With Down-scaling

Advanced and flexible GMP manufacturing process for mRNA is a strategic must-have


RNA Printer™ Prototype Unveiled February, 2019

New GMP process

Expected to be extremely valuable in hospital settings and in outbreak regions

Significantly accelerate pre-clinical to clinical development (parallel run of multiple trials)

Expected to result in significant cost reduction for development

Existing prototype in ongoing development

Financial Overview

€75m loan agreement with European Investment Bank (July)

Development of large-scale production in GMPIV suite

Provided in 3 tranches of €25m

First tranche in Q3 2020

Executing on Financial Strategy: Recent Announcements


€252m grant from the German Federal Ministry of Research

Announced on September 4

Grant to accelerate the development of COVID-19 vaccine candidate

Further support of rapid expansion of manufacturing capacities

Expected funding of up to:

€103m in 2020

€149m in 2021

Payments contingent on pre-defined milestones

Equity Non-dilutive

€300 m (German government) €120 million (GSK upfront)

€150 m (GSK)

€110 m (add. cumulative investments)

NEW

~$245m NASDAQ Initial Public Offering (August)

Launch of 15,333,332 common shares

~€560m in total equity financing & GSK Collaboration (July)

Equity at €1bn pre-money valuation of German government investment

Executing on Financial Strategy To Support Pipeline Progression

Key Financial Data


In USD million

Year endedDec. 31, 2018

Year endedDec. 31, 2019

Revenue from collaboration & licensing 14.0 19.0

R&D expenses

Research and pre-clinical developments

Clinical developments

Research manufacturing components

(45.5) (47.1)

G&A expenses

Personnel (Sr. Mgmt. / administrative)

Third party services (e.g. legal, audit, consulting)

Facilities and offices

(27.6) (53.4)

Net loss (77.7) (108.9)

In USD million

As of Dec. 31, 2018

As of Dec. 31, 2019

Cash and cash equivalents 23.3 33.4

Total assets 137.0 142.4

Total liabilities 102.0 198.0

Equity and convertible preferred stock 35.0 (46.7)

All amounts use a FX rate of ~1.09 EUR/USD

Leadership

An Experienced Team Leading the Global mRNA Revolution


CureVac Management

Pierre KemulaB.Sc.

Chief Financial Officer

Franz-Werner HaasLLD, LLM

Chief Executive Officer

Florian von der MülbePhD, MBA

Chief Production Officer & Co-Founder

Mariola Fotin-MleczekPhD

Chief Technology Officer

Bernd WinterhalterMD

Interim Chief Development Officer

Igor SplawskiPhD

Chief Scientific Officer

Investor Relations Contact

CureVac Investor Relations Contact


CVAC | NasdaqListed

CUSIP N2451R105

ISIN NL0015436031

WKN A2P71U

https://www.linkedin.com/company/curevac/@CureVac

https://twitter.com/CureVacRNA@CureVacRNA

https://de-de.facebook.com/CureVac/@CureVac

www.curevac.com

Dr. Sarah Fakih

Vice President Investor Relations

Friedrich-Miescher-Str. 1572076 TübingenGermany

Phone: +49 (0)7071 9883 -1298

Mobile: +49 (0)160 90496949

Email: [email protected]

[email protected]

CureVac www.curevac.com

RNActive® RNAdjuvant® RNAntibody®RNAntigen®PureMessenger®RNArt® The RNA Printer®RNAnimal® CVCM®

Thank you for your interest

Documents

Revolutionizing mRNA for Life · Key Company Highlights CureVac Investor Handout, October 2020 | 3 Strategic partnerships for clinical development and commercialization support Pioneer